Cash/Burn From SEC Filing For Period:
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH).
Click drug data to see upcoming trial info and prior data
Drug | Disease
Stage | Exp Date
See What The Community Is Saying - Click To See Full Post